Prescribing for people with acute rheumatic fever

Anna P. Ralph, Sara Noonan, Claire Boardman, Catherine Halkon, Bart J. Currie

Research output: Contribution to journalArticle

Abstract

Acute rheumatic fever and its consequence, rheumatic heart disease, remain important problems in remote indigenous Australian communities. Aboriginal and Torres Strait Islander people living in urban settings, Maori and Pacific Islanders, and immigrants from developing countries are also likely to be at elevated risk. Guidelines and resources are available for healthcare professionals working with at-risk populations, and for patients with acute rheumatic fever or rheumatic heart disease and their families. There have been some recent changes in Australian recommendations for antibiotic use, dose of aspirin, first-line choice for management of severe Sydenham’s chorea, and prevention of endocarditis. For individuals diagnosed with acute rheumatic fever, the recommended treatment to prevent recurrences and development of rheumatic heart disease is benzathine penicillin G administered as an intramuscular injection every four weeks.

LanguageEnglish
Pages70-75
Number of pages6
JournalAustralian Prescriber
Volume40
Issue number2
DOIs
Publication statusPublished - 2017
Externally publishedYes

Keywords

  • Benzathine penicillin
  • Rheumatic fever
  • Rheumatic heart disease
  • Sydenham’s chorea

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ralph, A. P., Noonan, S., Boardman, C., Halkon, C., & Currie, B. J. (2017). Prescribing for people with acute rheumatic fever. Australian Prescriber, 40(2), 70-75. https://doi.org/10.18773/austprescr.2017.011
Ralph, Anna P. ; Noonan, Sara ; Boardman, Claire ; Halkon, Catherine ; Currie, Bart J. / Prescribing for people with acute rheumatic fever. In: Australian Prescriber. 2017 ; Vol. 40, No. 2. pp. 70-75.
@article{a95216f39e4244ea9f61e83b9b56e71d,
title = "Prescribing for people with acute rheumatic fever",
abstract = "Acute rheumatic fever and its consequence, rheumatic heart disease, remain important problems in remote indigenous Australian communities. Aboriginal and Torres Strait Islander people living in urban settings, Maori and Pacific Islanders, and immigrants from developing countries are also likely to be at elevated risk. Guidelines and resources are available for healthcare professionals working with at-risk populations, and for patients with acute rheumatic fever or rheumatic heart disease and their families. There have been some recent changes in Australian recommendations for antibiotic use, dose of aspirin, first-line choice for management of severe Sydenham’s chorea, and prevention of endocarditis. For individuals diagnosed with acute rheumatic fever, the recommended treatment to prevent recurrences and development of rheumatic heart disease is benzathine penicillin G administered as an intramuscular injection every four weeks.",
keywords = "Benzathine penicillin, Rheumatic fever, Rheumatic heart disease, Sydenham’s chorea",
author = "Ralph, {Anna P.} and Sara Noonan and Claire Boardman and Catherine Halkon and Currie, {Bart J.}",
year = "2017",
doi = "10.18773/austprescr.2017.011",
language = "English",
volume = "40",
pages = "70--75",
journal = "Australian Prescriber",
issn = "0312-8008",
publisher = "National Prescribing Service",
number = "2",

}

Ralph, AP, Noonan, S, Boardman, C, Halkon, C & Currie, BJ 2017, 'Prescribing for people with acute rheumatic fever', Australian Prescriber, vol. 40, no. 2, pp. 70-75. https://doi.org/10.18773/austprescr.2017.011

Prescribing for people with acute rheumatic fever. / Ralph, Anna P.; Noonan, Sara; Boardman, Claire; Halkon, Catherine; Currie, Bart J.

In: Australian Prescriber, Vol. 40, No. 2, 2017, p. 70-75.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prescribing for people with acute rheumatic fever

AU - Ralph, Anna P.

AU - Noonan, Sara

AU - Boardman, Claire

AU - Halkon, Catherine

AU - Currie, Bart J.

PY - 2017

Y1 - 2017

N2 - Acute rheumatic fever and its consequence, rheumatic heart disease, remain important problems in remote indigenous Australian communities. Aboriginal and Torres Strait Islander people living in urban settings, Maori and Pacific Islanders, and immigrants from developing countries are also likely to be at elevated risk. Guidelines and resources are available for healthcare professionals working with at-risk populations, and for patients with acute rheumatic fever or rheumatic heart disease and their families. There have been some recent changes in Australian recommendations for antibiotic use, dose of aspirin, first-line choice for management of severe Sydenham’s chorea, and prevention of endocarditis. For individuals diagnosed with acute rheumatic fever, the recommended treatment to prevent recurrences and development of rheumatic heart disease is benzathine penicillin G administered as an intramuscular injection every four weeks.

AB - Acute rheumatic fever and its consequence, rheumatic heart disease, remain important problems in remote indigenous Australian communities. Aboriginal and Torres Strait Islander people living in urban settings, Maori and Pacific Islanders, and immigrants from developing countries are also likely to be at elevated risk. Guidelines and resources are available for healthcare professionals working with at-risk populations, and for patients with acute rheumatic fever or rheumatic heart disease and their families. There have been some recent changes in Australian recommendations for antibiotic use, dose of aspirin, first-line choice for management of severe Sydenham’s chorea, and prevention of endocarditis. For individuals diagnosed with acute rheumatic fever, the recommended treatment to prevent recurrences and development of rheumatic heart disease is benzathine penicillin G administered as an intramuscular injection every four weeks.

KW - Benzathine penicillin

KW - Rheumatic fever

KW - Rheumatic heart disease

KW - Sydenham’s chorea

UR - http://www.scopus.com/inward/record.url?scp=85019745298&partnerID=8YFLogxK

U2 - 10.18773/austprescr.2017.011

DO - 10.18773/austprescr.2017.011

M3 - Article

VL - 40

SP - 70

EP - 75

JO - Australian Prescriber

T2 - Australian Prescriber

JF - Australian Prescriber

SN - 0312-8008

IS - 2

ER -